Response to initial therapy predicts clinical outcomes in medullary thyroid cancer

Thyroid

Volumn 25, Issue 2, 2015, Pages 242-249

  Lindsey, Susan C ^a   Ganly, Ian ^b   Palmer, Frank ^b   Tuttle, R Michael ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CENTER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER THERAPY; CHILD; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDULLARY THYROID CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROID CANCER; TREATMENT RESPONSE; VERY ELDERLY; BLOOD; CARCINOMA, MEDULLARY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, MEDULLARY; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922547106     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2014.0277     Document Type: Article

References (41)

1. Tuttle RM, Ganly I 2013 Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. Oral Oncol 49:695-701.
2. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH 2000 Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139-1148.
3. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF 2005 Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metabolism 90:6077-6084.
4. Stepanas AV, Samaan NA, Hill CS Jr, Hickey RC 1979 Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer 43:825-837.
5. Meijer JA, le Cessie S, van den Hout WB, Kievit J, Schoones JW, Romijn JA, Smit JW 2010 Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol 72:534-542.
6. Laure Giraudet A, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E, Schlumberger M 2008 Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239-246.
7. Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K, Maeda M, Kumahara Y 1984 Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 199:461-466.
8. Saad MF, Fritsche HA Jr, Samaan NA 1984 Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 58: 889-894.
9. Machens A, Dralle H 2013 Benefit-risk balance of reoperation for persistent medullary thyroid cancer. Ann Surg 257:751-757.
10. Cohen R, Campos JM, Salaun C, Heshmati HM, Kraimps JL, Proye C, Sarfati E, Henry JF, Niccoli-Sire P, Modigliani E 2000 Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab 85: 919-922.
11. Machens A, Dralle H 2010 Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95:2655-2663.
12. Machens A, Schneyer U, Holzhausen HJ, Dralle H 2005 Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90:2029-2034.
13. Yip DT, Hassan M, Pazaitou-Panayiotou K, Ruan DT, Gawande AA, Gaz RD, Moore FD Jr, Hodin RA, Stephen AE, Sadow PM, Daniels GH, Randolph GW, Parangi S, Lubitz CC 2011 Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma. Surgery 150:1168-1177.
14. Machens A, Ukkat J, Hauptmann S, Dralle H 2007 Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg 142:289-293; discussion 294.
15. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B, Guilhem I 1998 Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d etude des tumeurs a calcitonine. Clin Endocrinol 48:265-273.
16. Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, Klar E 2001 Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 130:1044-1049.
17. Ito Y, Miyauchi A, Yabuta T, Fukushima M, Inoue H, Tomoda C, Uruno T, Kihara M, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F 2009 Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: experience of a single institution. World J Surg 33:58-66.
18. Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U, Dralle H 2000 Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88:1909-1915.
19. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, Schlumberger M 2003 Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88:2070-2075.
20. Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H 2004 Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg 28:1271-1274.
21. Gimm O, Ukkat J, Dralle H 1998 Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 22:562-567; discussion 567-568.
22. Abraham D, Jackson N, Gundara JS, Zhao J, Gill AJ, Delbridge L, Robinson BG, Sidhu SB 2011 MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res 17: 4772-4781.
23. Mehrotra PK, Mishra A, Mishra SK, Agarwal G, Agarwal A, Verma AK 2011 Medullary thyroid cancer: clinicopathological profile and outcome in a tertiary care center in North India. World J Surg 35:1273-1280.
24. Rios A, Rodriguez JM, Acosta JM, Balsalobre MD, Torregrosa N, Sola J, Perez-Flores D, Parrilla P 2010 Prognostic value of histological and immunohistochemical characteristics for predicting the recurrence of medullary thyroid carcinoma. Ann Surg Oncol 17:2444-2451.
25. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA, Jr. 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612.
26. National Comprehensive Cancer Network. Thyroid Carcinoma v2.2013. Available at: www.nccn.org/professionals/ physician-gls/f-guidelines.asp -thyroid (accessed July 9, 2013).
27. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341-1349.
28. Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, Vaisman M, Tuttle RM 2012 Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol 77:132-138.
29. Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM 2013 Outcomes of patients with differentiated thyroid cancer risk-stratified according to the american thyroid association and latin american thyroid society risk of recurrence classification systems. Thyroid 23:1401-1407.
30. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini F 2011 Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 165: 441-446.
31. Tuttle RM, Leboeuf R, Shaha AR 2008 Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol 97:712-716.
32. Vaisman F, Tala H, Grewal R, Tuttle RM 2011 In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 21:1317-1322.
33. Edge SE, Byrd DR, Carducci MA, Compton CA, Eds 2009 AJCC Cancer Staging Manual. Seventh edition. Springer-Verlag, New York, New York.
34. Boostrom SY, Grant CS, Thompson GB, Farley DR, Richards ML, Hoskin TL, Hay ID 2009 Need for a revised staging consensus in medullary thyroid carcinoma. Arch Surg 144:663-669.
35. Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M 2003 Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 88:1537-1542.
36. Rendl G, Manzl M, Hitzl W, Sungler P, Pirich C 2008 Long-term prognosis of medullary thyroid carcinoma. Clin Endocrino 69:497-505.
37. Franc S, Niccoli-Sire P, Cohen R, Bardet S, Maes B, Murat A, Krivitzky A, Modigliani E 2001 Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol 55:403-409.
38. Girelli ME, Dotto S, Nacamulli D, Piccolo M, De Vido D, Russo T, Bernante P, Pelizzo MR, Busnardo B 1994 Prognostic value of early postoperative calcitonin level in medullary thyroid carcinoma. Tumori 80:113-117.
39. Ismailov SI, Piulatova NR 2004 Postoperative calcitonin study in medullary thyroid carcinoma. Endocr Relat Cancer 11:357-363.
40. Kebebew E, Kikuchi S, Duh QY, Clark OH 2000 Longterm results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 135:895-901.
41. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F 2004 Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163-168.